MLYS - רווח לפני ריבית, מסים ופחת Mineralys Therapeutics, Inc.

The development of cardiovascular drugs is proceeding steadily without geopolitical risks. Operating cash flow before interest and taxes helps track the dynamics of this sector, where the current metric is 0.00. Mineralys Therapeutics (MLYS) is developing Lorundrostat to combat resistant hypertension. The business model assumes high scalability: a successful drug launch will generate colossal revenue with low production costs.

The market values Mineralys Therapeutics (MLYS) through the lens of the scalability of its antihypertensive developments, where minimal production costs upon commercialization create potential for explosive profit growth. Analysis of the EBITDA_Co metric allows for the tracking of daily real cash inflows from operating activities, eliminating reporting time lags and confirming the business's financial stability in real-time.